Synthesis and pharmacological characterization of 4-substituted-2- aminobicyclo[3.1.0]hexane-2,6-dicarboxylates: Identification of new potent and selective metabotropic glutamate 2/3 receptor agonists

Journal of Medicinal Chemistry

Volumn 56, Issue 11, 2013, Pages 4442-4455

  Monn, James A ^a   Valli, Matthew J ^a   Massey, Steven M ^a   Hao, Junliang ^a   Reinhard, Matthew R ^a   Bures, Mark G ^a   Heinz, Beverly A ^a   Wang, Xushan ^a   Carter, Joan H ^a   Getman, Brian G ^a   Stephenson, Gregory A ^a   Herin, Marc ^a   Catlow, John T ^a   Swanson, Steven ^a   Johnson, Bryan G ^a   McKinzie, David L ^a   Henry, Steven S ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 AMINO 4 (PHENYLTHIO)BICYCLO[3.1.0]HEXANE 2,6 DICARBOXYLIC ACID; 2 AMINO 4 AZIDOBICYCLO[3.1.0]HEXANE 2,6 DICARBOXYLIC ACID; 2 AMINO 4 FLUOROBICYCLO[3.1.0]HEXANE 2,6 DICARBOXYLIC ACID; 2 AMINO 4 HYDROXYBICYCLO[3.1.0]HEXANE 2,6 DICARBOXYL ACID; 2 AMINO 4 METHYLENEBICYCLO[3.1.0]HEXANE 2,6 DICARBOXYL ACID; 2 AMINO 4 OXOBICYCLO[3.1.0]HEXANE 2,6 DICARBOXYLIC ACID; 2,4 DIAMINOBICYCLO[3.1.0]HEXANE 2,6 DICARBOXYLIC ACID ACETIC ACID SALT; 4 ACETAMIDO 2 AMINOBICYCLO[3.1.0]HEXANE 2,6 DICARBOXYLIC ACID; DI TERT BUTYL 2 [(TERT BUTOXYCARBONYL)AMINO] 4 (P TOLYLSULFONYLOXY) BICYCLO[3.1.0]HEXANE 2,6 DICARBOXYLATE; DI TERT BUTYL 2 [(TERT BUTOXYCARBONYL)AMINO] 4 (PHENYLTHIO)BICYCLO[3.1.0]HEXANE 2,6 DICARBOXYLATE; DI TERT BUTYL 2 [(TERT BUTOXYCARBONYL)AMINO] 4 FLUOROBICYCLO[3.1.0]HEXANE 2,6 DICARBOXYLATE; DI TERT BUTYL 2 [(TERT BUTOXYCARBONYL)AMINO] 4 HYDROXYBICYCLO[3.1.0]HEXANE 2,6 DICARBOXYLATE; DI TERT BUTYL 2 [(TERT BUTOXYCARBONYL)AMINO] 4 METHYLENEBICYCLO[3.1.0]HEXANE 2,6 DICARBOXYLATE; DI TERT BUTYL 2 [(TERT BUTOXYCARBONYL)AMINO] 4 OXOBICYCLO[3.1.0]HEXANE 2,6 DICARBOXYLATE; DI TERT BUTYL 2 [(TERT BUTOXYCARBONYL)AMINO]BICYCLO [3.1.0]HEXANE 3 ENE 2,6 DICARBOXYLATE; DI TERT BUTYL 4 ACETAMIDO 2 [(TERT BUTOXYCARBONYL)AMINO]BICYCLO[3.1.0]HEXANE 2,6 DICARBOXYLATE; DI TERT BUTYL 4 AMINO 2 [(TERT BUTOXYCARBONYL) AMINO)]BICYCLO[3.1.0]HEXANE 2,6 \DICARBOXYLATE; DI TERT BUTYL 4 AMINO 2 [(TERT BUTOXYCARBONYL)AMINO]BICYCLO[3.1.0]HEXANE 2,6 DICARBOXYLATE; DI TERT BUTYL 4 AZIDO 2 [(TERT BUTOXYCARBONYL)AMINO]BICYCLO[3.1.0]HEXANE 2,6 DICARBOXYLATE; DI TERT BUTYL 4 BROMO 2 [(TERT BUTOXYCARBONYL) AMINO]BICYCLO[3.1.0]HEXANE 2,6 DICARBOXYLATE; DICARBOXYLIC ACID DERIVATIVE; EGLUMETAD; METABOTROPIC RECEPTOR AGONIST; TERT BUTYL 1 [(TERT BUTOXYCARBONYL)AMINO] 7 OXO 6 OXATRICYCLO[3.2.1.02,4]OCTANE 3 CARBOXYLATE; UNCLASSIFIED DRUG;

ARTICLE; DRUG BIOAVAILABILITY; DRUG SYNTHESIS; LOCOMOTION; MOLECULAR MODEL; NONHUMAN; RAT;

ADMINISTRATION, ORAL; AMINO ACIDS, DICARBOXYLIC; ANIMALS; ANTIPSYCHOTIC AGENTS; BICYCLO COMPOUNDS; CYCLOHEXANES; HUMANS; MALE; MODELS, MOLECULAR; MOTOR ACTIVITY; PSYCHOTIC DISORDERS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, METABOTROPIC GLUTAMATE; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84879052394     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm4000165     Document Type: Article

References (41)

1. O'Neill, M. J.; Fell, M. J.; Svensson, K. A.; Witkin, J. M.; Mitchell, S. N. Recent developments in metabotropic glutamate receptors as novel drug targets Drugs Future 2010, 35, 307-324
2. Niswender, C. M.; Conn, P. J. Metabotropic glutamate receptors: physiology, pharmacology and disease Annu. Rev. Pharmacol. Toxicol. 2010, 50, 295-322
3. Fell, M. J.; McKinzie, D. L.; Monn, J. A.; Svensson, K. A. Group II metabotropic glutamate receptor agonists and positive allosteric modulators as novel treatments for schizophrenia Neuropharmacology 2011, 62, 1473-1483
4. Moreno, J. L.; Sealfon, S. C.; Gonzalez-Maeso, J. Group II metabotropic glutamate receptors and schizophrenia Cell. Mol. Life Sci. 2009, 66, 3777-3785
5. Chaki, S. Group II metabotropic glutamate receptor agonists as potential drug for schizophrenia Eur. J. Pharmacol. 2010, 639, 59-66
6. Sanacora, G.; Zarate, C. A.; Krystal, J. H.; Manji, H. K. Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders Nature Rev. Drug Discovery 2008, 7, 426-437 (Pubitemid 351619114)
7. Witkin, J. M.; Marek, G. J.; Johnson, B. G.; Schoepp, D. D. Metabotropic glutamate receptors in the control of mood disorders CNS Neurol. Disord. Drug Targets 2007, 6, 87-100 (Pubitemid 46681770)
8. Schoepp, D. D.; Wright, R. A.; Levine, L. R.; Gaydos, B.; Potter, W. Z. LY354740, an mGlu2/3 receptor agonist as a novel approach to treat anxiety/stress Stress 2003, 6, 189-197 (Pubitemid 37210425)
9. Simmons, R. M. A.; Webster, A. A.; Kalra, A. B.; Iyengar, S. Group II mGluR receptor agonists are effective in persistent and neuropathic pain models in rats Pharmacol., Biochem. Behav. 2002, 73, 419-427 (Pubitemid 34765579)
10. Du, J.; Zhou, S.; Carlton, S. M. Group II metabotropic glutamate receptor activation attenuates peripheral sensitization in inflammatory states Neuroscience 2008, 154, 754-766
11. Kingston, A. E.; O'Neill, M. J.; Lam, A.; Bales, K. R.; Monn, J. A.; Schoepp, D. D. Neuroprotection by metabotropic glutamate receptor agonists: LY354740, LY379268 and LY389795 Eur. J. Pharmacol. 1999, 377, 155-165 (Pubitemid 29336037)
12. Battaglia, G.; Busceti, C. L.; Pontarelli, F.; Biagioni, F.; Fornai, F.; Paparelli, A.; Bruno, V.; Ruggieri, S.; Nicoletti, F. Protective role of group-II metabotropic glutamate receptors against nigro-striatal degeneration induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice Neuropharmacology 2003, 45, 155-166 (Pubitemid 36782528)
13. Schiefer, J.; Sprunken, A.; Puls, C.; Luesse, H.-G.; Milkereit, A.; Milkereit, E.; Johann, V.; Kosinski, C. M. The metabotropic glutamate receptor 5 antagonist MPEP and the mGluR2 agonist LY379268 modify disease progression in a transgenic mouse model of Huntington's disease Brain Res. 2004, 1019, 246-254 (Pubitemid 39078630)
14. Reiner, A.; Lafferty, D. C.; Wang, H. B.; Del Mar, N.; Deng, Y. P. The group 2 metabotropic glutamate receptor agonist LY379268 rescues neuronal, neurochemical and motor abnormalities in R6/2 Huntington's disease mice Neurobiol. Dis. 2012, 47, 75-91
15. Garcia, B. G.; Neely, M. D.; Deutch, A. Y. Cortical regulation of striatal medium spiny neuron dendritic remodeling in parkinsonism: modulation of glutamate release reverses dopamine depletion-induced dendritic spine loss Cereb. Cortex 2010, 20, 2423-2432
16. Arcella, A.; Carpinelli, G.; Battaglia, G.; D'Onofrio, M.; Santoro, F.; Ngomba, R. T.; Bruno, V.; Casolini, P.; Giangaspero, F.; Nicoletti, F. Pharmacological blockade of group II metabotropic glutamate receptors reduces the growth of glioma cells in vivo Neuro-Oncology 2005, 7, 236-245 (Pubitemid 41079133)
17. Ciceroni, C.; Arcella, A.; Mosillo, P.; Battaglia, G.; Mastrantoni, E.; Oliva, M. A.; Carpinelli, G.; Santoro, F.; Sale, P.; Ricci-Vitiani, L.; De Maria, R.; Pallini, R.; Giangaspero, F.; Nicoletti, F.; Melchiorri, D. Type-3 metabotropic glutamate receptors negatively modulate bone morphogenetic protein receptor signaling and support the tumorigenic potential of glioma-initiating cells Neuropharmacology 2008, 55, 568-576
18. Dunayevich, E.; Erickson, J.; Levine, L.; Landbloom, R.; Schoepp, D. D.; Tollefson, G. D. Efficacy and tolerability of an mGlu2/3 agonist in the treatment of generalized anxiety disorder Neuropsychopharmacology 2008, 33, 1603-1610 (Pubitemid 351684700)
19. Patil, S. T.; Zhang, L.; Martenyi, F.; Lowe, S. L.; Jackson, K. A.; Andreev, B. V.; Avedisova, A. S.; Bardenstein, L. M.; Gurovich, I. Y.; Morozova, M. A.; Mosolov, S. N.; Neznanov, N. G.; Reznik, A. M.; Smulevich, A. B.; Tochilov, V. A.; Johnson, B. G.; Monn, J. A.; Schoepp, D. D. Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized phase 2 clinical trial Nature Med. 2007, 13, 1102-1107 (Pubitemid 47517511)
20. Mezler, M.; Geneste, H.; Gault, L.; Marek, G. J. LY-2140023, a prodrug of the group II metabotropic glutamate receptor agonist LY-404039 for the potential treatment of schizophrenia. Curr. Opinion Invest Drugs 2010, 11, 833-845
21. Monn, J. A.; Valli, M. J.; Massey, S. M.; Wright, R. A.; Salhoff, C. R.; Johnson, B. G.; Howe, T.; Alt, C. A.; Rhodes, G. A.; Robey, R. L.; Griffey, K. R.; Tizzano, J. P.; Kallman, M. J.; Helton, D. R.; Schoepp, D. D. Design, synthesis and pharmacological characterization of (+)-2-aminobicyclo[3.1.0] hexane-2,6-dicarboxylic Acid (LY354740): a potent, selective and orally active group 2 metabotropic glutamate receptor agonist possessing anticonvulsant and anxiolytic properties J. Med. Chem. 1997, 40, 528-537 (Pubitemid 27080033)
22. Monn, J. A.; Valli, M. J.; Massey, S. M.; Hansen, M. M.; Kress, T. J.; Wepsiec, J. P.; Harkness, A. R.; Grutsch, J. L., Jr.; Wright, R. A.; Johnson, B. G.; Andis, S. L.; Kingston, A. E.; Tomlinson, R.; Lewis, R.; Griffey, K. R.; Tizzano, J. P.; Schoepp, D. D. Synthesis, pharmacological characterization and molecular modeling of heterobicyclic amino acids related to LY354740. Identification of LY379268 and LY389795: two new potent, selective and systemically active agonists for group II metabotropic glutamate receptors J. Med. Chem. 1999, 42, 1027-1040 (Pubitemid 29153432)
23. Monn, J. A.; Valli, M. J.; Massey, S. M.; Henry, S. S.; Stephenson, G. A.; Bures, M.; Herin, M.; Catlow, J.; Giera, D.; Wright, R. A.; Johnson, B. G.; Andis, S. L.; Kingston, A. E.; Schoepp, D. D. Synthesis and metabotropic glutamate receptor activity of S-oxidized variants of LY389795: identification of potent, selective and orally bioavailable agonists for mGlu2/3 receptors J. Med. Chem. 2007, 50, 233-240 (Pubitemid 46147704)
24. Dominguez, C.; Prieto, L.; Valli, M. J.; Massey, S. M.; Bures, M.; Wright, R. A.; Johnson, B. G.; Andis, S. L.; Kingston, A.; Schoepp, D. D.; Monn, J. A. Methyl substitution of 2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylate (LY354740) determines functional activity at metabotropic glutamate receptors: identification of a subtype selective mGlu2 receptor agonist J. Med. Chem. 2005, 48, 3605-3612 (Pubitemid 40664108)
25. Ceolin, L.; Kantamneni, S.; Barker, G. R. I.; Hanna, L.; Murray, L.; Warburton, E. C.; Robinson, E. S. J.; Monn, J. A.; Fitzjohn, S. M.; Collingridge, G. L.; Bortolotto, Z. A.; Lodge, D. Study of novel selective mGlu2 agonist in the temporo-ammonic input to CA1 neurons reveals reduced mGlu2 receptor expression in a Wistar substrain with an anxiety-like phenotype J. Neurosci. 2011, 31, 6721-6731
26. Hanna, L.; Ceolin, L.; Lucas, S.; Monn, J.; Johnson, B.; Collingridge, G. L.; Bortolotto, Z. A.; Lodge, D. Differentiating the roles of mGlu2 and mGlu3 receptors using LY541850, an mGlu2 agonist/mGlu3 antagonist Neuropharmacology 2013, 66, 114-121
27. Sanger, H.; Hanna, L.; Colvin, E. M.; Grubisha, O.; Ursu, D.; Heinz, B. A.; Findlay, J. D.; Vivier, R. G.; Sher, E.; Lodge, D.; Monn, J. A.; Broad, L. M. Pharmacological profiling of native group II metabotropic glutamate receptors in primary cortical neuronal cultures using a FLIPR Neuropharmacology 2013, 66, 264-273
28. Varie, D. L.; Beck, C. B.; Borders, S. K.; Brady, M. D.; Cronin, J. S.; Ditsworth, T. K.; Hay, D. A.; Hoard, D. W.; Hoying, R. C.; Linder, R. J.; Miller, R. D.; Moher, E. D.; Remacle, J. R.; Rieck, J. A., III. Design, development, and scale-up of a selective meso-epoxide desymmetrization process Org. Process Res. Dev. 2007, 11, 546-559
29. Henry, S. S.; Brady, M. D.; Laird, D. L. T.; Ruble, J. C.; Varie, D. L.; Monn, J. A. Org. Lett. 2012, 14, 2662-2665
30. Hao, J.; Reinhard, M.; Henry, S. S.; Seest, E. P.; Belvo, M. D.; Monn, J. A. Simple conversion of fully protected amino acids to zwitterions Tetrahedron Lett. 2012, 53, 1433-1434
31. Schoepp, D. D.; Johnson, B. G.; Wright, R. A.; Salhoff, C. R.; Mayne, N. G.; Wu, S.; Cockerham, S. L.; Burnett, J. P.; Belagaje, R.; Bleakman, D.; Monn, J. A. LY354740 is a potent and highly selective group II metabotropic glutamate receptor agonist in cells expressing human glutamate receptors Neuropharmacology 1997, 36, 1-11 (Pubitemid 27115837)
32. Wu, S.; Wright, R. A.; Rockey, P. K.; Burgett, S. G.; Arnold, J. S.; Rosteck, P. R., Jr; Johnson, B. G.; Schoepp, D. D.; Belagaje, R. Mol. Brain Res. 1998, 53, 88-97
33. Muto, T.; Tsuchiya, D.; Morikawa, K.; Jingami, H. Structures of the extracellular regions of the group II/III metabotropic glutamate receptors Proc. Natl. Acad. Sci. U. S. A. 2007, 104, 3759-3764 (Pubitemid 47189144)
34. Maestro, version 9.2; Schrodinger LLC: New York, 2011.
35. The PyMOL Molecular Graphics System, version 1.2r3; Schrodinger LLC, New York, 2011.
36. PDB ID 3sm9. Wernimont, A. K.; Dong, A.; Seitova, A.; Crombet, L.; Khutoreskaya, G.; Edwards, A. M.; Arrowsmith, C. H.; Bountra, C.; Weigelt, J.; Cossar, D.; Dobrovetsky, E. Crystal structure of metabotropic glutamate receptor 3 precursor in presence of LY341495 antagonist. Structural Genomics Consortium, New York, 2011; to be published.
37. James, J. K.; Nakamura, M.; Nakazato, A.; Zhang, K. E.; Cramer, M.; Brunner, J.; Cook, J.; Chen, W. G. Drug Metab. Dispos. 2005, 33, 1373-1381
38. Rorick-Kehn, L. M.; Johnson, B. G.; Burkey, J. L.; Wright, R. A.; Calligaro, D. O.; Marek, G. J.; Nisenbaum, E. S.; Catlow, J. T.; Kingston, A. E.; Giera, D. D.; Herin, M. F.; Monn, J. A.; McKinzie, D. L.; Schoepp, D. D. J. Pharmacol. Exp. Ther. 2007, 321, 308-317
39. Johnson, J. T.; Mattiuz, E. L.; Chay, S. H.; Herman, J. L.; Wheeler, W. J.; Kassahun, K.; Swanson, S. P.; Phillips, D. L. Drug Metab. Dispos. 2002, 30, 27-33
40. Davies, B.; Morris, T. Physiological parameters in laboratory animals and humans Pharm. Res. 1993, 10, 1093-1095 (Pubitemid 23211439)
41. A radiolabelled form of 18f has been prepared and utilized in rodent autoradiography studies: Wright, R. A.; Johnson, B. G.; Zhang, C.; Salhoff, C.; Kingston, A. E.; Calligaro, D. O.; Monn, J. A.; Schoepp, D. D.; Marek, G. J. CNS distribution of metabotropic glutamate 2 and 3 receptors: Transgenic mice and [3H]LY459477 autoradiography Neuropharmacology 2013, 66, 89-98